AstraZeneca PLC (AZN)
75.17
+0.14
(+0.19%)
USD |
NASDAQ |
Apr 26, 16:00
75.17
0.00 (0.00%)
After-Hours: 19:30
AstraZeneca Cash from Financing (TTM): -6.567B for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -6.567B |
| September 30, 2023 | -6.634B |
| June 30, 2023 | -5.338B |
| March 31, 2023 | -5.114B |
| December 31, 2022 | -6.823B |
| September 30, 2022 | -7.516B |
| June 30, 2022 | -5.944B |
| March 31, 2022 | 2.64B |
| December 31, 2021 | 3.649B |
| September 30, 2021 | 2.49B |
| June 30, 2021 | 3.591B |
| March 31, 2021 | -2.572B |
| December 31, 2020 | -2.203B |
| September 30, 2020 | 13.00M |
| June 30, 2020 | -3.942B |
| March 31, 2020 | -3.429B |
| December 31, 2019 | -1.765B |
| September 30, 2019 | -3.503B |
| June 30, 2019 | -622.00M |
| March 31, 2019 | -2.079B |
| December 31, 2018 | -2.044B |
| September 30, 2018 | -324.00M |
| June 30, 2018 | -3.563B |
| March 31, 2018 | -1.557B |
| December 31, 2017 | -2.936B |
| Date | Value |
|---|---|
| September 30, 2017 | -3.228B |
| June 30, 2017 | -1.172B |
| March 31, 2017 | -2.005B |
| December 31, 2016 | -1.324B |
| September 30, 2016 | 3.264B |
| June 30, 2016 | 3.26B |
| March 31, 2016 | 2.086B |
| December 31, 2015 | 878.00M |
| September 30, 2015 | -2.255B |
| June 30, 2015 | -2.523B |
| March 31, 2015 | -3.062B |
| December 31, 2014 | -2.705B |
| September 30, 2014 | -3.655B |
| June 30, 2014 | -3.481B |
| March 31, 2014 | -3.027B |
| December 31, 2013 | -3.047B |
| September 30, 2013 | -3.773B |
| June 30, 2013 | -2.903B |
| March 31, 2013 | -3.717B |
| December 31, 2012 | -4.923B |
| September 30, 2012 | -6.079B |
| June 30, 2012 | -8.687B |
| March 31, 2012 | -8.952B |
| December 31, 2011 | -9.321B |
| September 30, 2011 | -9.46B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-7.516B
Minimum
Sep 2022
3.649B
Maximum
Dec 2021
-2.610B
Average
-3.429B
Median
Mar 2020
Cash from Financing (TTM) Benchmarks
| GSK PLC | -7.019B |
| Amgen Inc | 21.05B |
| Sanofi SA | -- |
| Viking Therapeutics Inc | 873.23M |
| Fusion Pharmaceuticals Inc | 142.01M |